Liver as a target for oligonucleotide therapeutics

Area of Science:

• Pharmacology
• Genetics
• Molecular Biology

Background:

• Oligonucleotide therapeutics represent a novel drug class with potential for targeting previously undruggable genetic disorders.
• Unlike gene therapy, these synthetic molecules offer specific, transient genetic modulation without integrating into the host genome.
• They encompass various modalities including siRNA, antisense oligonucleotides, and miRNA-targeting agents.

Purpose of the Study:

• To review the landscape of oligonucleotide-based therapeutics.
• To highlight the progress and challenges in delivering these agents, particularly focusing on liver-targeted applications.
• To underscore the liver's significance as a target organ for oligonucleotide therapies due to its central metabolic and synthetic roles.

Main Methods:

• Review of existing literature on oligonucleotide therapeutic mechanisms and delivery systems.
• Focus on preclinical and clinical data for liver-specific oligonucleotide delivery strategies.
• Analysis of the biological rationale for targeting liver-expressed genes.

Main Results:

• Oligonucleotide therapeutics demonstrate high specificity for genetic targets, reducing off-target effects.
• Significant advancements have been made in hepatic delivery of oligonucleotides, with promising preclinical and clinical results.
• The liver's extensive metabolic functions and role in synthesizing key proteins make it an ideal target for oligonucleotide-based interventions.

Conclusions:

• Effective intracellular delivery remains a primary hurdle for oligonucleotide therapeutics.
• Liver-targeted oligonucleotide therapies have shown considerable success, indicating a viable path for clinical translation.
• The liver's central role in numerous physiological processes positions it as a key organ for developing oligonucleotide-based medicines.